Bio-Thera focuses on therapeutics for cardiovascular, cancer and autoimmune conditions. Credit: sergey kolesnikov/Shutterstock.

Bio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for the Simponi (golimumab) biosimilar, BAT2506 in the US.

Bio-Thera will develop, manufacture and supply BAT2506. It is set to obtain an upfront payment of $21m and could earn up to $143.5m in development and commercial milestones.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Intas will handle commercialisation in the US market through its US speciality division, Accord BioPharma.

Accord BioPharma US president Chrys Kokino stated: “Our exclusive commercialisation agreement with Bio-Thera strengthens our biosimilar pipeline, a vital component of our US growth strategy.

“We’re investing heavily in biosimilars through external partnerships plus our own clinical efforts because we believe in their vast potential to drive patient and provider-centric solutions. Bio-Thera’s global experience makes them an excellent partner.”

The human immunoglobulin G 1 (IgG1) monoclonal antibody golimumab is used to target a pro-inflammatory molecule, tumour necrosis factor alpha (TNF-α).

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The binding of the molecule to TNF-α can lead to a decrease in inflammatory markers.

Golimumab is approved for treating ulcerative colitis, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis in the US and Europe.

Based in Guangzhou, China, Bio-Thera Solutions focuses on therapeutics for cardiovascular, cancer, autoimmune and eye conditions. It also focuses on biosimilars for existing branded biologics.

The company has advanced multiple candidates into late-stage development, with four approved products: Qletli and Betagrin in China, and Tofidence/BAT1806 and Avzivi/Pobevcy in the US, European Union and China.

In April 2021, Biogen and Bio-Thera entered an agreement to develop, manufacture and commercialise BAT1806, an anti-interleukin-6 (IL-6) receptor monoclonal antibody.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact